HELEN S. KIM

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

EOM Pharmaceutical Holdings, Inc.

Filing Date Source Excerpt
2013-08-16 Helen S. Kim Ms. Kim has served as a director since August 2011. ... The following table sets forth information concerning the compensation paid to each of our non-employee directors during 2012 for their services rendered as directors. ... Helen Kim $61,875 in stock awards and $63,332 in option awards. Total $125,207. ... Member of our Nominating and Corporate Governance Committee, Member of our Finance Committee.
2014-04-30 Helen S. Kim (1)(2)(4) (5)(7) 51 Director ... (1) Member of our Compensation Committee ... (2) Member of our Nominating and Corporate Governance Committee ... (4) Member of our Finance Committee ... Ms. Kim was appointed to serve on the Compensation Committee effective December 6, 2013 ... Director Compensation for Fiscal Year 2013 ... Helen S. Kim ... Total 148,479

Viracta Therapeutics, Inc.

Filing Date Source Excerpt
2010-04-29 Helen S. Kim is currently the chief business officer of NGM Biopharmaceuticals, Inc. Ms. Kim was appointed to the Board on July 24, 2009. Ms. Kim's total compensation for 2009 was $25,602.
2011-04-21 Helen S. Kim is currently the chief business officer of NGM Biopharmaceuticals, Inc., where she has served since August 2009. ... Ms. Kim was appointed as a director pursuant to the Investor Rights Agreement executed in connection with Growth Equity Opportunities Fund, LLC's purchase of our securities in the Private Placement. ... The following table sets forth the compensation information for our non-employee directors, as well as Dr. Young, the current Chairman of our Board and former Executive Chairman, for the year ended December 31, 2010. ... Helen S. Kim Fees Earned or Paid in Cash $30,000, Option Awards $5,393, Total $35,393.
2012-04-23 Helen S. Kim currently serves as a strategic advisor to NGM Biopharmaceuticals, Inc. Ms. Kim was appointed as a director pursuant to the Investor Rights Agreement executed in connection with Growth Equity Opportunities Fund, LLC's purchase of our securities in the Private Placement. The Board has concluded that Ms. Kim should serve on our Board due to her corporate development, managerial and scientific expertise. Director Compensation Table shows total compensation of $102,690.
2013-04-25 Helen S. Kim currently serves as a strategic advisor to NGM Biopharmaceuticals, Inc., where she served as the chief business officer from August 2009 to January 2012. ... On March 22, 2012, Ms. Kim was appointed as a member of the Audit Committee. ... The following table sets forth the compensation information for our non-employee directors for the year ended December 31, 2012. ... Helen S. Kim total compensation $84,647.
2014-04-24 Helen S. Kim serves on the Audit Committee. The compensation table shows total compensation of $109,796 for 2013.
2015-04-28 Helen S. Kim currently serves as a strategic advisor to NGM Biopharmaceuticals, Inc., where she served as the chief business officer from August 2009 to January 2012. Prior to joining NGM, Ms. Kim was the chief executive officer of TRF Pharma, where she served from December 2008 to June 2009. Prior to her service at TRF Pharma, Ms. Kim served as the president and chief executive officer of Kosan Biosciences, Inc. from January 2008 to July 2008. From August 2003 to December 2007, Ms. Kim served as chief program officer of the Gordon and Betty Moore Foundation and from 2002 to 2003 as chief business officer of Affymax, Inc. Prior to her service at Affymax, Ms. Kim was senior vice president of corporate development of Onyx Pharmaceuticals, Inc. from 1999 to 2002. Ms. Kim also served as the vice president of strategic marketing at Chiron Corporation from 1989 to 1998. Ms. Kim previously served on the board of Immunocellular Therapeutics, Ltd., a publicly traded biotechnology company, and currently serves on the board of West Coast Clinical Trial Global, a privately held global contract research organization and ForSight VISION4, Inc., a private eye care device company. Ms. Kim holds a B.S. in Chemical Engineering from Northwestern University and an M.B.A. from the University of Chicago. The Board has concluded that Ms. Kim should serve on our Board due to her corporate development, managerial and scientific expertise, which the Board believes makes her an important resource for the Board as it assesses both tactical and strategic business decisions. Director Compensation Table: Helen S. Kim Fees Earned or Paid in Cash ($): $50,000, Option Awards ($): $87,038, Total ($): $137,038.
2016-04-25 Helen S. Kim resigned from the Board and Audit Committee on March 23, 2016. The Director Compensation Table shows total compensation of $134,652.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22